Single-use Cystoscope Market

Single-use Cystoscope Market Outlook (2023 – 2033)

The global revenue from the single-use cystoscope market was about US$ 76.5 Million in 2022, with the global market expected to grow at a CAGR of 8.5% to reach a valuation of about US$ 188.7 Million by the end of 2033.

As assessed by Persistence Market Research, flexible video single-use cystoscope held a market share of around 86.6% in the global market, in 2022. Overall, single-use cystoscope market sales account for around 0.25% of revenue share in the global urology device market, which was valued at around US$ 30.4 Billion in 2022.

The single-use flexible cystoscope provides consistent quality without the need for reprocessing cleaning, or repairs in between procedures, and there is no risk of cross-contamination because sterile cystoscopes are used and discarded after each operation. Unlike rigid cystoscopes, flexible cystoscopes works in combination of both optical system and the working/irrigation channel into a single unit.

Cystoscopy procedure allows the urologist view the urinary tract, particularly the bladder, urethra, and the openings to the ureter. Cystoscopy is helpful in diagnosis and treatment of urinary tract problems. This include early signs of urinary tract cancers, painful urination (dysuria), stone in urinary tract, urinary tract infection (UTI), narrowing, enuresis (involuntary urination), blockage, or bleeding (hematuria).

Sales Analysis of Market from 2015 – 2022 Vs Market Outlook for 2023 – 2033

The global single-use cystoscope market recorded a historic CAGR of 7.4% in the last 7 years from 2015 to 2022 due to high preference for flexible single-use cystoscope for various urinary tract problems.

Key players and hospitals are working for advanced techniques for minimizing cross-contamination as infection rates and healthcare acquired infections (HAIs) are on the rise. Single-use cystoscope helps decrease incidence of infections (both internal and external) and thus, demand for the same is expected to gain momentum over the forecast period.

The single-use cystoscope is portable, self- contained with its own light source, and video recording features, less recovery time due to minimally invasive procedure allowing it to be used in any office, clinics and hospitals.

Reusable cystoscope requires reprocessing after every procedure to maintain the sterility of cystoscope. Emerging countries lack inadequate reprocessing facilities as reprocessing requires proper facilities and trained professionals, thus creating more scopes for disposable or single-use medical devices. The potential reprocessing cost commonly associated with reusable endoscopes can also be minimized with use of single-use cystoscope.

Most companies offer online and international shipping, so the device can be ordered from anywhere globally. Online websites also aid in the promotion of products, resulting in better opportunities for players in the near future.

• For instance, companies such as NeoScope and UroViu offer online ordering services for single-use cystoscopes.

Organizations such as World Health Organization (WHO) and Center for Disease Control and Prevention (CDC) are conducting various awareness campaigns and programs which include training sessions and guidelines to educate people about hospital acquired infections and thus helping to prevent their occurrence and improve patient safety.

Thus, all these favorable opportunities are anticipated to expand the global market.

How Can the Global Market Grow?

“Cystoscope Widening the Scope for Diagnosis of Urinary Tract Problems”

Cystoscopes are used to diagnose and treat urinary tract problems such as recurring UTI. A cystoscope can also be used to diagnose problems such as blood in the urine (hematuria). A cystoscope is also commonly used to diagnose a urethral or ureteral blockage or narrowing. Urologists use cystoscope to remove stones from the bladder and urethra and to treat urinary incontinence. To treat specific conditions, special tools can be passed through the cystoscope. A very small bladder tumor, for example, may be removed during cystoscopy.

• According to a 2021 article published in the journal Frontiers in Public Health on UTI among geriatric patients, UTI/bacterial infections (upper and lower urinary tract) are extremely common in the elderly population and a consistent cause of hospitalisation globally. UTIs cause about 7 Million hospital visits, 1 Million emergency visits, and 100,000 hospitalisations each year, which is about 25% of all infections among the elderly.

UTI diagnosis and treatment are more difficult in the elderly population than in the younger population due to underlying risk factors such as older age, diabetes mellitus, dyslipidemia, hypertension, chronic kidney disease, spinal cord injuries, weakened immunity, and catheterization.

• Study of 460 patients published in this article found asymptomatic bacteriuria 31.9%, cystitis 37.6%, prostatitis 6.4%, pyelonephritis 13.9%, and urosepsis 10.2%.

Single-use cystoscopes are used to have a better visual of the bladder and urethra due to the rising need for early detection and treatment of prostate and bladder cancer, which is driving the growth of the global market.

• According to WHO data 2020, estimated prostate cancer cases were 1,414,259 (7.3%) and number of deaths due prostate cancer cases were 375,304 (3.8%). Urological cancer, on the other hand, is the 10th most common cancer type worldwide. The number of bladder cancer cases diagnosed was 600,000, with about 200,000 deaths caused by this disease.

Can the Market Growth Be Affected in Any Way?

“Unskilled Professionals, Few Variety, and Side Effect after Cystoscopy Use”

Delivery of high-quality cystoscopy services largely depends on the capability of the cystoscopy specialist. Globally, the demand for cystoscopic procedures is increasing. Single-use cystoscope is also a new technology penetrating the market requiring highly skilled professionals for its operation. Hence, the growth of the global market can be affected due to the limited number of skilled professionals.

Currently, only few market players are offering single-use cystoscope in the market, thus buyers are left with fewer options to choose from. There are also many substitutes and alternatives available for single-use cystoscope in the market, thus limiting the growth of the global market. Many healthcare facilities have already invested in reusable cystoscopies. Thus the presence of few market players are hampering the growth of the global market over the forecast period.

There are several side effects associated with single-use cystoscope, which may last for one or two days after cystoscopy, such as mild burning urination, mild discomfort in kidney and bladder area, need to urinate more frequently, and small amount of blood in urine. Thus, these side effects are anticipated to hamper the adoption of the global market.

Country-wise Insights

Why is the U.S. Market Booming?

“Increased Cystoscope Use in Finding Out Curable Causes of Recurrent UTIs”

The U.S. market held around 33.7% market share of the global market in 2022 because of prevalence of recurrent UTIs, especially in women.

• According to published article on UTI in Therapeutic Advances in Urology journal in 2019, UTIs are the most common outpatient infections in the U.S. There are an estimated 250,000 cases of pyelonephritis annually in the U.S., with a higher frequency among females.
• According to published article on recurrent UTIs in StatPearls by National Library of Medicine in 2022, the lifetime prevalence of at least one symptomatic UTI in women is estimated to be over 50%, with about 26% chances of a recurrence since the initial UTI.
• According to published article on cystoscopy findings in females with recurrent UTI in Nephro-Urology Monthly journal in 2018, cystoscopy can aid in the discovery of some curable causes of recurrent UTIs, particularly in patients with atypical presentations such as obstructive symptoms, urinary incontinence, identification of potential pre-malignant or malignant lesions, and guiding patients’ follow-up.

Will the U.K. Be a Lucrative Market for Single-use Cystoscope Market?

“High Bladder Cancer Rate and Its High Cost Need Cystoscope for Cancer Early Detection”

The U.K. market held at about 5.6% market share of the global market in 2022 and it is anticipated to expand the global market due to the use of cystoscope for early detection of bladder cancer.

• According to Cancer Research UK, there are 10,300 new bladder cancer cases and 5,555 deaths in the U.K. each year. Bladder cancer has a 50% mortality rate and the highest recurrence rate of any known cancer, reaching up to 80%.
• Cancer Research UK also reports that prostate cancer is the most prevalent cancer in men, with at about 47,700 new cases diagnosed each year in the U.K.

In the U.K., bladder cancer treatment is expensive, and hence it is anticipated to expand the global market of single-use cystoscope for early detection of cancer.

• According published article on bladder cancer effect on the U.K. healthcare costs and patient health-related quality of life in Clinical Genitourinary Cancer in 2020, non–muscle-invasive bladder cancer (NMIBC) will experience in health-related quality of life and experience significant costs, primarily in the case of a grade 3 recurrence or a development to muscle-invasive bladder cancer.

How is India Emerging As a Prominent Market?

“Unhygienic Toilet Practices will Rise the UTI”

India held a market share of about 4.4% of the global market in 2022 and it is expected to increase the global market due to inadequate and low quality sanitary infrastructure is the key challenge to avoid UTIs.

• According to published article on sanitation and chance of UTI occurrence among women from low economic families in the International Journal of community Medicine and Public Health in 2019, poor sanitation facilities are the leading cause of many health issues in slums populace. A cross-sectional study was done on 616 women living in 33 different slums with age from 18 to 60. UTI was found to be prevalent in 19.6% of people. The occurrence was higher among young women under the age of 30 (23.2%). In the absence of an individual toilet, women adopted behaviors such as alter dinner to escape toilet use at night (26.6%), reducing liquid intake (10.7%), and urine holding habit (21.3%) to decrease the frequency of toilet visits. All of these behaviors were found to be significantly related to UTI.

Category-wise Insights

Which Type of Product is Driving Demand Within the Global Market?

“More Clinical Utilization of Flexible Video Single-Use Cystoscope Over Other Single-Use Cystoscope”

Flexible single-use cystoscope share was about 86.6% of the global market in terms of revenue in 2022 because of the clinical utilisation of flexible single-use cystoscope over rigid single-use cystoscope.

Flexible video single-use cyctoscope allows urologist and physician to see the urethra and bladder more clearly due to camera lenses and lower irrigation fluid flow in flexible cystoscopies. Flexible cystoscopy can be performed while the patient is awake. Thus, flexible cystoscopes are patient-friendly, less invasive and easy to use, propelling the flexible single-use cystoscope sector forward.

• According to a published article in the Journal of Endourology in 2022 on the comparison of single-use flexible cystoscope and standard reusable device for bladder cancer surveillance and lower urinary tract symptoms investigation, the single-use flexible cystoscope is superior to standard flexible cystoscope regarding the completion of procedure, and image quality, light quality, and controllability, hence Single-use flexible cystoscopes are a safe and effective alternative.

Which End User is Helping to Expand the Global Market?

“Various Cystoscopy Procedures Need to be done in the Hospitals by Skilled Health Workers”

By end user segment, hospitals segment held around 39.2% share of the global market in 2022 due to healthcare reimbursement policies and availability of skilled professionals for cystoscopy.

Cystoscopy is primarily done in hospitals because of availability of trained medical professionals or doctors to remove foreign bodies like bladder stones from the bladder using the proper surgical techniques.

• According to published article on epidemiology of urolithiasis in the International Journal of Clinical Practice in 2022, the condition's incidence grew from 77.78 Million occurrence cases in 1990 to 115.55 Million in 2019, by 48.57%.
• According to published article on urolithiasis in the StatPearls of National Library of Medicines in 2022, the urolithiasis is widespread and causes a significant larger number of hospital admissions.

Other reasons of use of cystoscope in hospitals by expertise are due to detect bladder cancer, cystitis, and benign prostatic hyperplasia as well as to look into the causes of bladder signs and symptoms, like hematuria, frequent UTIs, incontinence, and dysuria. In order to identify bladder cancer, this method can be done to acquire a biopsy or tissue sample from the bladder lining. Catheter insertion can also be done by cystoscopy (thin drainage tube of urine).

Other reason to expand hospitals end user is the healthcare reimbursement facility by various countries.

• For instance, Medicare has approved the reimbursement policies in the U.S., which allows the payment of US$ 170.28 at national level for separate procedure of flexible cystoscope with CPT code 52000

Competition Landscape

The key players are concentrating on launching new devices, developing devices that improve efficiency. The key players are primarily focused on new product line innovation and product expansion with partnership of domestic companies for commercialising high quality, cost-effective, disposable endoscopic products.

A few examples of strategies acquired by the key players:

• In May 2020, Ambu medical device maker company launched aScope 4 Cysto single-sue cytsoscope with improved workflow and productivity benefits. The new product can be used to monitor bladder cancer, remove stents, and perform other common cystoscopy procedures.
• In May 2021, Asieris Pharmaceuticals has a partnership agreement with UroViu for supply of these single-use cystoscopy system in China. UroViu Corporation manufactured Uro-G and Uro-3500 and approved by the US Food and Drug Administration (FDA) in 2018 and 2021, respectively. Now, in February 2023, Asieris Pharmaceuticals declared the acceptance of the registration for the single-use, Uro-G electronic cystoscope cannula and Uro-3500 electronic endoscope image processor by National Medical Products Administration (NMPA).

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the single-use cystoscope market, which are available in the full report.

Single-use Cystoscope Industry Report Scope

Key Segments Covered in Single-use Cystoscope Industry Research

Product

• Flexible Single-use Cystoscope
• Semi-Flexible Single-use Cystoscope

End User

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers

Region

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

To know more about delivery timeline for this report Contact Sales